- Aurinia Pharmaceuticals has one of the most important milestones in its history in a few weeks.
- Next January 22, 2021 is the PDUFA where the FDA will decide the approval of the candidate drug Voclosporin.
- Voclosporin approval by the FDA is almost assured thanks to the very good phase III trial data presented last December 2019.
- Estimates of the potential revenues that Voclosporin could generate worldwide once approved range from $1.5B to $3B per year.
For further details see:
Aurinia Pharmaceuticals Offers Good Entry Opportunity Before Next PDUFA For Voclosporin